Latest News

All Articles

Filter by:
Topic
Drug Updates

Pharmacist’s Application to Practice:
Mirvetuximab soravtansine-gynx

November 14, 2022

Shrina Patel, PharmD, BCOP, Clinical Pharmacy Specialist at University of Texas MD Anderson Cancer Center writes about Mirvetuximab soravtansine-gynx.

Scan of human lungs
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Tremelimumab

November 10, 2022

Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Teclistamab-cqyv

October 25, 2022

Gavyn Walsh, PD3 Oncology Pharmacy Intern and Erin Kelley, PharmD, BCOP at M Health Fairview Masonic Cancer Clinic write about teclistamab-cqyv

Late Breaking News

Adapting Investigational Drug Services During a Pandemic

October 06, 2022

Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Futibatinib

September 30, 2022

Mei Ka Fong, Pharm.D., BCOP Clinical Pharmacist Coordinator Levine Cancer Institute, Atrium Health writes about Futibatinib

Pharmacist talking to a customer
Advocacy

The Value of Oncology Pharmacists Op-Ed

August 01, 2022

With Drug Shortages and Errors on the Rise, Oncology Pharmacists are Vital to Navigate Treatment in the Era of a Pandemic

Pharmacist talking to a customer
Advocacy

The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling

July 06, 2022

The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens

Journal Club

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

June 06, 2022

Ghassan K. Abou-Alfa, M.D., M.B.A. abou-alg@mskcc.org, George Lau, M.D., F.R.C.P., Masatoshi Kudo, M.D., Ph.D., Stephen L. Chan, M.D., Robin Kate Kelley, M.D., Junji Furuse, M.D., Ph.D., Wattana Sukeepaisarnjaroen, M.D., +24 for the HIMALAYA Investigator

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey

May 11, 2022

Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. The purpose of this survey was to characterize the

Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/ Oncology Pharmacy Association (HOPA) on April 1, 2022 at the association’s annual conference in Boston, Massachusetts.
HOPA Members

HOPA President Brings Expertise and Unique Perspective to Hematology/Oncology Pharmacy Practice

April 01, 2022

Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/ Oncology Pharmacy Association (HOPA) on April 1, 2022 at the association’s annual conference in Boston, Massachusetts.

HOPA Issues Drug Shortages Brief

January 19, 2022

Drug shortages present serious challenges for HOPA members in their efforts to provide optimal care to individuals affected by cancer. Shortages of drugs that are essential for the treatment and care of individuals with cancer result in c

Large B-Cell Lymphoma
Journal Club

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

December 11, 2021

Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects.